The prosomatostatin-derived peptides somatostatin-14 (Som-14) and somatostatin-28 (Som-28) are believed to act as neurotransmitters in the central nervous system. To examine possible mechanisms by which these peptides induce their physiological actions in brain, the effects of Som-14 and Som-28 on voltage-dependent K+ currents in rat cerebral cortical neurons in culture were examined by using whole-cell patch-clamp techniques. Som-14 increased a delayed rectifier K+ current (IK) in the cortical neurons, while Som-28 reduced IK in the neurons, both in a concentration-dependent manner.
IK in the neurons, both in a concentration-dependent manner.
Som-14 and Som-28 could induce opposite changes in IK in the same neurons. Elevating intracellular cAMP in the cortical neurons did not modify the effects of Som-14 or Som-28 on IK, indicating that the peptides can regulate this ionic current through cAMP-independent mechanisms. Pretreatment of the neocortical cells with pertussis toxin, which inactivates inhibitory GTP-binding proteins, abolished both Som-14 and Som-28 modulation of IK, indicating that Som-14 and Som-28 receptors are coupled to IK via GTP-binding proteins. These studies show that Som-14 and Som-28 can induce opposite biological effects, suggesting that Som-14 and Som-28, acting through distinct receptors, may function as different neurotransmitters or neuromodulators.
Immunocytochemical studies have shown that three prosomatostatin-derived peptides, somatostatin-28 (Som-28), somatostatin-14 (Som- 14) , and Som-28- (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) , are present in the central nervous system (1, 2) . Som-28 is a 28-residue precursor for the 14-residue carboxyl-terminal Som-14 and the amino-terminal Som-28-(1-14) (3) . A number of studies have shown that Som-14 and Som-28 can function as neurotransmitters or neuromodulators in the nervous system (4, 5) . Som-14 and Som-28 can be released from neurons in a calcium-dependent manner (6) . Receptors for Som-14 and Som-28 have been identified in the brain (7) . Furthermore, these peptides regulate transmitter release in brain and ionic conductances in neurons (4, (8) (9) (10) (11) (12) .
It is generally believed that Som-28 and Som-14 exert similar biological effects, and both Som-28 and Som-14 have been proposed to interact with the same receptors in the anterior pituitary and central nervous system (5) . However, several studies have suggested that Som-28 may act through a receptor population distinct from the one that mediates Som-14 effects. Mandarino et al. (13) and Brown et al. (14) reported that Som-28 is more potent than Som-14 in blocking insulin release from beta cells of the pancreas. In contrast, Som-14 is more potent in inhibiting glucagon secretion from islet alpha cells. Som-28 and Som-14 have been shown to have a reverse rank order of potency in blocking hormone release and calcium mobilization in several clonal cell lines derived from the anterior pituitary (15) . Furthermore, separate binding sites for radioactive Som-14 and Som-28 ligands have been suggested to exist in the rat brain (16) . Thus, it is possible that Som-28 can bind to specific Som-28 receptors distinct from those responsive to Som-14.
If Som-14 and Som-28 act upon different receptors, they may induce different physiological effects. Such a finding would strongly support the hypothesis that these two peptides are distinct neurotransmitters or neuromodulators. To determine whether Som-14 and Som-28 induce different physiological actions, we have examined the effects of these two peptides on ionic currents in cultured rat neocortical neurons. These cells express somatostatin receptors and the neurons release both Som-14-like and Som-28-like immunoreactivities (17) . We report that Som-14 enhances a voltagedependent potassium current in these cortical neurons, whereas Som-28 decreases the same current. This study shows that Som-14 and Som-28 can induce different biological actions and suggests that they may be distinct neurotransmitters or neuromodulators.
METHODS
Cell Culture. Primary rat cerebral cortical cultures were prepared as previously described (18) . Cerebral cortices were removed from 16-or 17-day-old fetuses and dissociated in 0.03% trypsin in Dulbecco's modified Eagle's medium (DMEM). Cells were subsequently dispersed by trituration and plated onto 35-mm Petri dishes containing polylysinecoated coverslips at a density of 0.5-1.0 x 106 viable cells per dish in 1.5 ml of growth medium (DMEM supplemented with 10% Hyclone calf serum, 10% Ham's F-12 medium with 2 mM glutamine, penicillin at 25 units/ml, and streptomycin at 25 ,g/ml). Cultures were maintained at 36-37°C in a humidified 5% CO2 incubator. Proliferation of glial cells was prevented by the addition of cytosine arabinonucleoside to the cultures 7-10 days after the initial subculturing. Rat neocortical neurons cultured for 2-5 weeks were used in the present study.
Electrophysiological 
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NaOH. To isolate potassium currents, 5 1LM tetrodotoxin and 5 mM CoC12 were used to block sodium and calcium currents. Patch electrodes were filled with a solution containing 140 mM KCI, 1 mM MgCI2, 10 mM EGTA, 10 mM Hepes, pH 7.3 with KOH. Patch pipettes were fabricated from N51A borosilicate glass and had a resistance of 2-5 Mtl in control saline solutions. Somatostatin analogs and control saline solutions were applied to neurons by using pressure ejection from blunt micropipettes. Recordings were made at room temperature (21-240C).
RESULTS Depolarizing voltage steps from a holding potential of -80 mV evoked outward potassium currents in the neurons under conditions in which voltage-dependent sodium and calcium currents were blocked (Fig. 1) . Some neurons express both a transient outward K+ current (IA) and a delayed rectifier K+ current (IK) (Fig. lA) , while other neurons express only IK (Fig. 1C) (20) . Since calcium currents were blocked and the electrode contained 10 mM EGTA, calcium-activated K+ currents were not a component of the K+ currents measured in the present studies.
Application of Som-14 onto the cortical neurons induced a concentration-dependent increase ofa persistent K+ outward current ( Figs. 1 and 2 ). The effects of Som-14 were generally reversible with brief buffer washes. In cells that expressed both IA and IK, Som-14 increased the outward current throughout the duration of the voltage steps in a pattern which suggests a predominant effect on IK ( Fig. 1 A and B) ; in cells that expressed only IK, Som-14 facilitated this K+ current ( Fig. 1 C and D (20) . After the perfusion of 100 nM Som-14 onto this neuron, both peak and plateau potassium currents were enhanced. HBS, Hanks' A predominantly enhances IK* Of the 78 cells studied, 53 responded to Som-14 perfusion with an increase in persistent K+ outward current, while 24 showed no response and 1 showed a decrease in potassium currents.
In contrast to the effects of Som-14, Som-28 decreased IK in the cortical neurons (Fig. 3) . Forty of 60 neurons examined showed a decrease in the delayed rectifer K+ currents after Som-28 application. Nineteen cells examined had no response, and one cell responded with an increase in potassium currents. The inhibitory effect of Som-28 on IK was reversible (Fig. 3 A and C) and concentration dependent (Fig. 2) .
To determine whether Som-14 and Som-28 receptors in the same neurons regulate IK, the two peptides were applied in random order to the same cell and the subsequent effect on the outward K+ current was measured (Fig. 4) . Of 18 cells examined, 5 responded to Som-28 with a decreased IK and to Som-14 with an increased IK (Fig. 4A) ; 5 cells responded only to Som-28 (decreased IK) and not to Som-14 ( Fig. 4B) , and 5 cells responded to Som-14 application with an increase in potassium currents but did not respond to Som-28 application (Fig. 4C) (2) , but Som-28-(1-14) is generally reported to be biologically inactive (5) . To determine whether this peptide is biologically active in this system, the effect of 100 nM Som-28-(1-14) on K+ currents in the neocortical neurons was examined. In 11 of 12 cells tested, 100 nM Som-28-(1-14) did not affect IKE Those neurons that were unresponsive to Som-28-(1-14) did respond to either Som-14 or Som-28 with changes in IK.
Previously, Som-14 was reported to enhance a K+ current that is regulated by muscarinic agonists (M current) in hippocampal neurons (9) . This effect of Som-14 could be blocked by the muscarinic agonist carbachol (9) . In the presence of 50,uM carbachol, Som-14 (100 nM) still increased the voltage-dependent K+ currents in the cultured cortical neurons to an extent similar to that in control cells. This finding suggests that Som-14 effects on IK in neocortical neurons were unrelated to the previously described M current.
Intracellular second messengers such as cAMP have been shown to mediate the regulatory effects of neurotransmitters on voltage-dependent ion channels (21) (22) (23) . Som-14 is known to decrease cAMP in the brain and peripheral tissues (24) . To determine whether the different effects of and Som-28 on K+ currents in rat neocortical neurons are related to contrasting actions of the peptides on cAMP production, the peptides were tested for their ability to regulate adenylate cyclase activity in membranes of the cultured rat neocortical cells. Som-14 and Som-28 inhibited basal adenylate cyclase activity of rat neocortical cells by 38% ± 3% and 24% ± 2%, respectively. To test the role of cAMP in mediating the effects of Som-28 and Som-14 on IK, 100 ,uM cAMP and 0.5 mM isobutylmethylxanthine (IBMX, a phosphodiesterase inhibitor) were added to the recording electrode, thereby allowing the intracellular content of cAMP to be greatly elevated, as previously described (25 (11, 12) . One approach to establish whether inhibitory GTP-binding proteins couple receptors to effector systems is through the use of pertussis toxin. Pertussis toxin catalyzes ADP-ribosylation of inhibitory GTP-binding proteins, thereby inactivating those proteins and uncoupling receptors from their effector systems. In neocortical cells pretreated with pertussis'toxin (300 ng/ml for 24 hr),'Som-14 Both Som-14 and Som-28 appear to regulate IK through cAMP-independent mechanisms. This is suggested by their abilities to increase or decrease IK in cells with high intracellular concentrations of cAMP and the phosphodiesterase inhibitor IBMX. A cyclic-AMP independent mechanism was also proposed for the ability of Som-14 to enhance an inward rectifying K+ current in locus coeruleus and submucous plexus neurons (11, 12) . The present findings would also suggest that somatostatin receptors are capable of interacting with multiple cellular effector systems in the same neuron. These effector systems appear to include adenylate cyclase, K+ channels, and, in preliminary studies (26) , voltagedependent Ca2+ channels.
Somatostatin receptors in brain are coupled to GTPbinding proteins (25) . Recent electrophysiological studies have shown that a number of neurotransmitter receptors are linked to ionic conductance channels by coupling to G1 or G.
or other subclasses of GTP-binding protein (for review, see ref. 27 ). Both the Som-14 and Som-28 receptors are coupled to the K+ channels mediating IK via inhibitory GTP-binding proteins. This is indicated by the ability of pertussis toxin to abolish both Som-14 and Som-28 modulation of IK in neocortical neurons. Since Som-14 and Som-28 induce opposite effects on IK, it is likely that different inhibitory GTP-binding proteins couple Som-14 receptors and Som-28 receptors to the K+ channels mediating IK. The GTP-binding proteins that couple the somatostatin receptor subtypes to the K+ channels in neocortical neurons remain to be identified.
